Nodality, Inc., a South San Francisco, CA-based biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, raised $15.5m in venture capital financing.
The round was led by Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE:PFE), and Laboratory Corporation of America Holdings (NYSE:LH), with additional participation from previous investors, including Kleiner Perkins Caulfield & Byers, TPG Biotechnology, and Maverick Capital.
The capital infusion will be used to support commercial activities associated with the company’s launch of its first test in acute myelogenous leukemia, as well as to advance ongoing and new research and development programs in other hematologic malignancies, autoimmune diseases, and solid tumors.
FinSMEs
22/03/2010